Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 126, pseudogene (RNU6-126P) is a human genomic pseudogene and a member of the U6 small nuclear RNA paralog family. It is not translated into protein and is not believed to produce functional non-coding RNA. Unlike the canonical U6 small nuclear RNA (snRNA), which is a critical component of the spliceosome and frequently used as a normalization control in expression studies, pseudogene variants like RNU6-126P lack demonstrated biological activity, disease association, or utility as drug targets or biomarkers. It is primarily annotated for completeness of genome mapping, without known physiological or therapeutic relevance[1]. If you require details on functional U6 snRNA genes (e.g., RNU6-1), those are well-studied as reference genes in gene expression normalization protocols and may have some indication as cancer biomarkers, but RNU6-126P lacks such properties[1][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 126, pseudogene (RNU6-126P).